anti-PD1 immunotherapyneoadjuvant anti-PD-1-based therapynon-small cell lung carcinomaNSCLCnon-small-cell lung cancerJ Immunother Cancer
…ntified CD8+FoxP3+ cells as a positive predictor of response to anti-PD1 immunotherapy in non-small-cell lung cancer (NSCLC). We further developed the…